Le Lézard
Classified in: Health, Science and technology, Business
Subject: DIV

Lilly Announces 8 Percent Dividend Increase


INDIANAPOLIS, Dec. 11, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today announced an 8 percent increase in its quarterly dividend. The dividend for the first quarter of 2018 will be $0.5625 per share on outstanding common stock. This raises the annual indicated rate to $2.25 per share. 

The dividend is payable March 9, 2018, to shareholders of record at of the close of business on February 15, 2018.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.  F-LLY   

Refer to:

Lauren Zierke; [email protected]; (317) 277-6524 (Media)


Phil Johnson; [email protected]; (317) 655-6874 (Investors)

 

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

 

SOURCE Eli Lilly and Company


These press releases may also interest you

at 03:05
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to...

at 03:00
Charging an electric vehicle (EV) at home is certainly more convenient than using a public charging station, but what are the other benefits? Along with convenience, the...

at 02:15
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a...

at 02:05
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and Maze Therapeutics, Inc. (Head Office: South San Francisco, California, USA; Chief Executive Officer: Jason Coloma, Ph.D.;...

at 02:00
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwardsProvides Novavax with cash and an equity investment totalling approximately $1.2 billion...

at 01:00
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the extraordinary shareholders'...



News published on and distributed by: